Convertible Note Stacks in 2026: Low Caps, MFNs

The trap isn’t the note, it’s the stack you accidentally create

Convertible notes and SAFEs were invented to remove friction: close money fast, defer valuation, and avoid an early priced round when the company is still figuring out product, market, and narrative.

In 2026, they still do that, until they don’t.

The “convertible note trap” isn’t a single clause. It’s the way seemingly founder-friendly terms (low caps, generous MFNs, and pro-rata side letters) interact over multiple raises to produce:

a shadow priced round that no one negotiated coherently,

an overcrowded cap table with hard-to-model rights, and

an effective pre-money valuation at Series A that is either too high (investor pushback) or too low (founder dilution), with too much negotiation debt attached.

The result is a Series A process where investors spend more time on cleanup than on conviction, and where the cleanest path is often a valuation haircut, a restructure, or a new lead who demands terms to compensate for the mess.

This article is a practical field guide to how founders walk into the trap, how Series A investors see it, and what to do instead, without moralizing about notes/SAFEs, which remain valid tools when used with restraint.

> Scope note: “Convertible notes” below includes notes and SAFEs. The economic mechanics differ (debt vs. contract, maturity/interest vs. not), but the cap/discount/MFN/pro-rata issues show up in both.

---

Why this problem is sharper in 2026

Several 2024–2026 patterns intensified the trap:

More bridge rounds, fewer clean resets. Many companies raised 2–4 incremental rounds between seed and Series A (or seed extension → seed-2 → bridge) using notes/SAFEs. Each one added rights, caps, and exceptions.

Valuation anchoring is back. After the 2021 peak and subsequent correction, investors are more valuation-sensitive, and cap table optics matter again. A low cap can make the early note look “cheap,” but the downstream math can create a de facto valuation that’s inconsistent with the current market.

Institutional seed investors behave more like Series A investors. Many seed funds now request pro-rata, MFNs, and information rights routinely. One investor is manageable; five investors each with bespoke side letters is not.

AI and deep-tech timelines created longer pre-Series A periods. Longer R&D cycles mean more interim financing, more stacked instruments, and more opportunities to accumulate rights.

This isn’t just “legal complexity.” It is negotiation leverage. Series A investors dislike uncertainty; uncertainty demands either price concessions or structure concessions.

---

The mechanics: how notes/SAFEs are supposed to work

A quick shared model (you likely know this, but we need the frame):

A note/SAFE converts into equity at the next priced round, typically at the better of:

- a discount to the Series A price (e.g., 20%), or
- a valuation cap (e.g., $10M cap), giving an implied conversion price.

Sometimes there’s a Most Favored Nation (MFN) clause allowing an investor to adopt more favorable terms from later notes.

Sometimes there are side letters granting pro-rata rights (ability to maintain ownership in future rounds), information rights, or other protections.

Any one of these can be fine. The trap emerges when you combine them across multiple financings, with inconsistent caps, MFNs that “infect” earlier rounds, and pro-rata promises that over-allocate your next round before you even meet the lead.

---

Trap #1: Low valuation caps that turn your seed into a stealth priced round

What founders think a low cap does

A low cap feels founder-friendly because it “gets the deal done” and signals upside to early investors. It also feels temporary: “It only affects conversion later.”

What it actually does

A low cap sets an economic floor on how cheap early investors buy in, regardless of what your Series A price would otherwise be.

If you raise a meaningful amount on a low cap, you effectively ran a priced round without negotiating:

board composition,

protective provisions,

option pool sizing,

major investor rights,

or a coherent ownership target for the lead.

Instead, you let those economics be determined by a future event (Series A) that now has to reconcile past promises.

Why Series A investors care

A lead Series A investor typically wants a target ownership (often 15–25%, depending on stage, market, and check size). If conversion from notes consumes too much of the cap table at a low price, the lead must choose among three unattractive options:

Pay up (accept less ownership or invest more than intended),

Force a lower pre-money (hurting founders and prior equity holders), or

Demand restructure mechanics (more legal work, more negotiation, more risk).

Even when everyone is rational, this creates a perception problem: “This company has already sold too much of itself too cheaply, or too confusingly.”

The subtle second-order effect: option pool double taxation

Many priced rounds include an option pool refresh that is carved out pre-money (i.e., dilutive to founders and prior holders). If a low cap already caused significant dilution at conversion, the pool refresh can compound founder dilution dramatically.

A real-world style pattern

Seed SAFE #1: $5M cap

Seed SAFE #2 (three months later): $8M cap

Bridge SAFE: $12M cap + MFN

Total SAFE amount: $3–5M

At Series A, the “best price” conversion mechanics often mean a big portion converts at $5M or $8M economics, then MFN or “best of” language pulls others down. A lead who wanted to price at $25–30M pre may find the effective cap table behaves like a $12–18M pre after accounting for conversion and pool.

It’s not that $25–30M is impossible. It’s that the path there becomes adversarial: someone has to “give.”

Red flags investors see immediately

More than ~20–25% fully-diluted conversion from notes/SAFEs before the Series A money.

Early caps dramatically below current traction (e.g., $4–6M caps with credible Series A narrative).

Multiple caps across many instruments without a consolidation plan.

(These are not universal thresholds; they’re heuristics. But they are the heuristics many investors actually use.)

---

Trap #2: Pro-rata side letters that pre-sell your Series A

Why pro-rata feels harmless

Pro-rata is often framed as “standard” and “fair”, early backers get to maintain their ownership if they keep supporting the company.

And when it’s one major seed investor at a reasonable percentage, it’s often fine.

How it quietly kills pricing power

The problem is not pro-rata in isolation. It’s the sum of pro-rata rights promised to multiple parties, especially when those rights are:

contractual (side letter),

not conditioned on meaningful future participation,

not limited to a “major investor” threshold,

and not subordinated to the Series A lead’s allocation preferences.

If enough of your next round is already spoken for, your Series A lead faces:

reduced ability to build a syndicate,

reduced ability to allocate to high-signal co-investors,

reduced ownership for the risk taken,

and a harder time using the round to recruit strategic investors (e.g., a top-tier AI infra fund, a vertical specialist, or a prominent angel).

Allocation is a hidden currency. When you’ve given it away contractually, you lose leverage.

The practical impact: “There’s no room for us”

In 2026, many Series A rounds are not huge. If you’re raising $12M and $6M is effectively reserved due to stacked pro-rata claims, the lead may only get $4–5M at best unless they upsize.

If they need $8–10M to justify the work (ownership target + board seat + time), they may simply pass.

Red flags

Pro-rata rights granted to small checks (e.g., anyone who put in $50–100k).

Side letters with no major investor threshold.

“Super pro-rata” language (right to buy more than pro-rata).

Pro-rata stacking across multiple rounds without clear prioritization.

What sophisticated investors ask for during diligence

Series A counsel will request:

every side letter,

a pro-rata schedule,

the exact mechanism (who can exercise, timing, notice),

whether the company can cut back allocations.

If you cannot answer cleanly, you’re already paying a price: slower diligence, more uncertainty, and a weaker negotiating posture.

---

Trap #3: MFNs that “infect” your whole financing history

MFN basics

MFN (Most Favored Nation) clauses typically allow an investor to adopt later instruments’ terms if those later terms are more favorable.

MFNs are sometimes limited to specific terms (e.g., information rights) and sometimes broad enough to cover caps/discounts or other economics.

Why MFNs create nonlinear downside

MFNs can turn what you thought was a sequence of separate financings into a single blended instrument, where the best investor terms propagate backward.

Example:

SAFE A: $10M cap

SAFE B: $14M cap, but includes a 25% discount and a liquidity preference-like shadow term (or a more aggressive definition of “Company Sale” conversion)

SAFE A has MFN

Now SAFE A holders may elect SAFE B terms. Suddenly your earlier “simpler” SAFE becomes the more complex one.

Even if MFN is limited to “economic terms,” that can still mean caps/discounts shift in ways you didn’t model.

The Series A investor’s concern

The lead wants:

predictable conversion math,

no surprise rights surfacing from obscure later docs,

clear cap table at signing.

MFNs create tail risk: the company can’t be sure which investors will elect into which terms until the conversion event. That uncertainty is poison during priced round negotiation.

Red flags

Broad MFN language (“any more favorable terms” without carve-outs).

MFN across multiple SAFEs/notes with inconsistent templates (e.g., YC SAFE + custom SAFE + note).

MFN combined with side letters that may themselves change.

---

How the three traps compound each other

Individually, low caps, pro-rata, and MFNs are manageable. Together, they create a system where:

Low caps drive heavy dilution at conversion.

MFNs spread the lowest cap (or the most investor-friendly economics) across the whole stack.

Pro-rata side letters reserve much of the new round for existing holders, leaving insufficient room for the Series A lead.

The Series A lead then does the only rational thing: they demand compensation.

Compensation usually takes one (or more) of these forms:

lower pre-money valuation,

larger option pool refresh,

more investor-friendly terms (participation, stronger protective provisions, pay-to-play, etc.),

requirement to renegotiate/waive certain note/SAFE rights as a closing condition.

Even if you “get the round done,” you may have traded away long-term flexibility.

---

The downstream symptoms: what it looks like when you’re already in the trap

Founders often realize too late because the early money closed quickly and felt like momentum. The symptoms usually appear during Series A diligence:

Your data room becomes a scavenger hunt. Missing side letters, inconsistent SAFE versions, unclear totals.

Your lead insists on a cap table model they control. This isn’t always adversarial; it’s risk management.

You get asked to “clean up the seed.” Translation: waive MFNs, cap pro-rata, consolidate instruments, or convert early.

Term sheet drifts. The initial verbal valuation doesn’t survive the conversion math.

Your existing investors start negotiating with each other. This is the worst case: you’re no longer the central negotiator.

---

Multiple perspectives: why these terms exist (and when they’re fair)

It’s easy to villainize investors here, but the truth is more nuanced.

The investor’s argument

Low caps compensate for early risk and lack of information.

Pro-rata ensures they can maintain exposure to winners and justifies the time spent helping.

MFNs protect against the company selling better terms to later investors.

All reasonable, especially when investors are writing meaningful checks and providing real value.

The founder’s argument

Notes/SAFEs are supposed to reduce negotiation overhead.

Side letters proliferate because saying “yes” is easier than fighting.

Founders often don’t have pricing power early, and speed matters.

Also reasonable.

The problem is that “reasonable locally” can be “disastrous globally.” Fundraising is path-dependent.

---

Red flags checklist (2026 edition)

Use this as a pre-Series A internal audit.

Cap-related red flags

Multiple caps with wide dispersion (e.g., $6M, $10M, $18M).

Total outstanding notes/SAFEs > ~15–25% of fully diluted at expected Series A pricing.

Caps far below credible Series A comps for your traction.

Rights-related red flags

Any MFN that applies to economics (cap/discount) without tight limits.

Pro-rata granted broadly via side letters.

Pro-rata not defined with a “major investor” threshold.

Side letters that include veto-like controls or unusual information rights.

Process-related red flags

No single source of truth for instruments and side letters.

Investors using different templates (YC SAFE + custom SAFE + convertible note).

No counsel review on each close.

If you see 2–3 of these together, you should assume you will pay for it at Series A, either in time, valuation, or structure.

---

Negotiation language: how to ask for what you need without blowing up the deal

This section is intentionally concrete. Exact wording should be vetted by counsel, but these are the concepts and phrases that tend to work.

1) Cap discipline: keep optionality

Goal: Avoid a cap that sets your future priced round up for conflict.

Possible framing:

“We’re targeting a priced seed/Series A in the next X months; we want the cap to reflect that trajectory without forcing a restructure later.”

“We can do a cap, but we need it to be within a range that preserves room for a lead to take meaningful ownership.”

Tactic: If an investor pushes for a low cap, offer:

a slightly better discount,

a small warrant (notes), or

a defined conversion floor/ceiling that doesn’t distort the Series A.

2) MFN limitations: keep it narrow and non-economic

Goal: MFN should not be a blank check.

Founder-friendly MFN concept: MFN applies only to administrative terms (e.g., information rights), not valuation cap/discount.

Possible language concept:

“MFN applies to non-economic terms only and explicitly excludes valuation cap, discount rate, and conversion mechanics.”

“MFN election must be made within a fixed period after issuance of the later instrument.”

3) Pro-rata: reserve it for major investors and keep it flexible

Goal: Preserve allocation flexibility for the Series A lead.

Possible language concept:

“Pro-rata rights are granted only to Major Investors (minimum investment of $X).”

“Pro-rata is subject to cutback to accommodate the lead investor’s minimum ownership target.”

“Pro-rata applies to the investor’s ownership as of immediately prior to the financing and excludes increases due to conversion discounts.”

Practical compromise:

Give pro-rata to 1–2 key investors, not everyone.

If many small investors demand it, consider a pooled SPV (but be careful, SPVs add their own dynamics).

4) Side letters: standardize or don’t do them

Goal: Avoid bespoke obligations.

Possible language concept:

“We’re keeping all investors on a single standard SAFE/note without side letters to ensure the next round is clean.”

“If we provide pro-rata, it will be via the main instrument on a standardized basis.”

5) “Clean-up cooperation” clause (underrated)

Goal: Ensure investors commit to reasonable waivers needed for a priced round.

Conceptual ask:

“Investor agrees to execute customary waivers or amendments reasonably requested to consummate a Qualified Financing, provided economic terms are not adversely affected beyond the agreed instrument.”

This is not a license to rewrite the deal; it’s insurance against small technical blockers.

---

Safer structures in 2026 that preserve pricing power

If you want speed without sabotaging Series A, consider these patterns.

Structure A: One round, one instrument, one cap

When it fits: You are raising a single seed round over a short window.

Use one SAFE or note form.

One cap (or cap + discount) for everyone.

No MFN.

Pro-rata only for major investors, standardized.

Why it works: Minimizes dispersion and prevents backward infection.

Structure B: Tranche with pre-agreed step-up (instead of MFN)

When it fits: You expect to raise again soon, but want clear economics.

Round 1 cap: $X

Round 2 cap: $Y (higher), pre-declared

Why it works: Investors understand the deal improves for earlier risk without MFN complexity.

Structure C: Priced seed with simple docs

When it fits: You already have enough traction that valuation is discussable.

A priced seed round can be cleaner than a sprawling SAFE stack, because you settle:

valuation,

ownership,

board/controls,

option pool,

major investor rights,

in one coherent package.

The tradeoff is time/legal cost, but in 2026 that cost is often lower than the Series A cleanup cost of a messy seed.

Structure D: Cap conversion or early conversion before Series A

When it fits: You already have notes/SAFEs outstanding.

Options include:

Pre-Series A conversion into shadow preferred or common (rarely ideal, but sometimes useful),

Consolidation into a single amended instrument with consistent cap/discount,

Waivers to remove MFN/pro-rata overhang.

This usually requires a “yes” from key investors; it’s easier if you do it before you are desperate for Series A.

---

Practical modeling: how to sanity-check your note stack

You don’t need perfect modeling to detect danger; you need directional clarity.

Step 1: Build a conversion waterfall

For each instrument, list:

amount invested

cap

discount

MFN (yes/no, scope)

pro-rata rights (yes/no, amount)

Then compute conversion under 2–3 plausible Series A pre-money values.

Step 2: Estimate the Series A lead’s room

Decide what a credible lead will want:

ownership % target

check size range

Then ask: after note conversion and honoring pro-rata, is there enough allocation for that lead without upsizing the round beyond reason?

Step 3: Add the option pool refresh

Model at least two cases:

10% pre-money pool refresh

15% pre-money pool refresh

If founders end up with an unexpectedly low post-Series A ownership, the “trap” is real.

---

What to do if you’re already trapped (triage plan)

1) Consolidate information fast

Gather every instrument and side letter.

Create a single cap table model with scenarios.

Identify who has MFN and what it covers.

2) Identify your “decision holders”

Usually 1–3 investors control whether cleanup is possible. Focus negotiations there.

3) Offer reasonable consideration for waivers

Asking investors to waive rights for nothing can work if they trust you, but often you’ll need to trade:

a small additional SAFE allocation at the new cap,

improved information rights,

or explicit pro-rata (limited) in exchange for removing MFN or broad pro-rata.

4) Make cleanup part of the Series A narrative (carefully)

Sophisticated leads don’t mind cleanup if:

it’s well-scoped,

it’s pre-negotiated with key holders,

it doesn’t threaten closing.

The worst scenario is discovering the mess after the term sheet.

---

References and further reading (foundational, not hype)

Y Combinator SAFE documents and explanations (canonical SAFE variants; helpful for understanding standard terms and where customizations create complexity): https://www.ycombinator.com/documents

NVCA model legal documents (baseline for priced rounds; useful for understanding how investors expect rights to be structured in an equity financing): https://nvca.org/model-legal-documents/

Cooley GO and other major firm guides on convertible notes/SAFEs and financing mechanics (practical legal perspectives; check the latest firm updates):

- Cooley GO resources: https://www.cooleygo.com/
- Gunderson Dettmer insights: https://www.gunder.com/insights/
- Fenwick startup resources: https://www.fenwick.com/insights

SEC materials on fundraising exemptions and investor status (relevant context if you are stacking many small investors): https://www.sec.gov/

(These references are not endorsements; they’re widely used starting points.)

---

A clear opinionated takeaway

Notes and SAFEs aren’t the enemy. Undisciplined terms are.

If you want maximum Series A pricing power in 2026, optimize for:

coherence (one instrument, one cap, minimal bespoke terms),

predictability (no broad MFNs, no surprise economics), and

allocation flexibility (pro-rata for true major investors only, with clear cutbacks).

The founder-friendly move is not accepting every “small” investor request to close faster. The founder-friendly move is protecting the future round that actually sets your long-term ownership, governance, and trajectory.

If you remember one sentence: a messy note stack is a delayed negotiation, not a shortcut.